# Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD

> **NCT01253928** · PHASE4 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 16 (estimated)

## Conditions studied

- ESRD

## Interventions

- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT01253928
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-03
- **Primary completion:** 2011-06
- **Final completion:** —
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2010-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253928, "Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01253928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*